Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

131.64 +0.21 (+0.16%)
Official Closing Price Updated: 7:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
50 51 Next >
Novartis Ag (NVS) Q4 2024 Earnings Call Transcript
NVS earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading
The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 
Via Stocktwits
Topics Intellectual Property
Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker
The company's biggest moneymaker is expected to face off with lower-cost generics this summer. 
Via Investor's Business Daily
Topics Earnings
US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact
US stock futures climbed on Friday, pointing to a third straight week of gains fueled by strong corporate earnings. 
Via Benzinga
Uncovering Dividend Opportunities with NYSE:NVS.
Uncovering Dividend Opportunities with NOVARTIS AG-SPONSORED ADR (NYSE:NVS). 
Via Chartmill
Balancing Dividends and Fundamentals: The Case of NYSE:NVS.
Exploring NOVARTIS AG-SPONSORED ADR (NYSE:NVS)'s dividend characteristics. 
Via Chartmill
Why the dividend investor may take a look at NYSE:NVS.
Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) qualifies as a good dividend investing stock. 
Via Chartmill
Novartis Q4: Earnings Beat Estimates, CEO Dismisses Entresto Patent Expiration Worries
Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's U.S. patent expiration while projecting continued growth in 2025. 
Via Benzinga
Topics Earnings Intellectual Property
When you look at NYSE:NVS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
NOVARTIS AG-SPONSORED ADR is a hidden gem, featuring undervaluation and robust fundamentals. NYSE:NVS showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
Earnings Scheduled For January 31, 2025
 
Via Benzinga
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement. 
Via Benzinga
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
AI Pharma: 2 Paths to AI-Powered Drug Investment
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients. 
Via MarketBeat
Topics Artificial Intelligence
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals. 
Via Benzinga
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end. 
Via Benzinga
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients. 
Via Benzinga
Don't overlook NYSE:NVS—it's a hidden gem with strong fundamentals and an attractive price tag.
Investors should take notice ofNOVARTIS AG-SPONSORED ADR (NYSE:NVS)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones. 
Via Benzinga
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions. 
Via Benzinga
Topics Lawsuit
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?
Via The Motley Fool
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
For those who appreciate value investing, NYSE:NVS is a compelling option with its solid fundamentals.
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval. 
Via Investor's Business Daily
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks. 
Via Benzinga
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
Janux Therapeutics reports updated clinical data for JANX007, highlighting significant efficacy, safety, and durability in advanced prostate cancer patients. 
Via Benzinga
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up to $2.9 billion, including milestones and royalties. 
Via Benzinga
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
The deal focuses on the company's treatment for Huntington's disease. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
50 51 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.